FFA
VERV

Farther Finance Advisors’s Verve Therapeutics VERV Stock Holding History

Farther Finance Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,477
Closed -$27.8K – 5085
2025
Q2 		$27.8K Buy
2,477
+2,449
+8,746% +$14K ﹤0.01% 2469
2025
Q1 		$116 Hold
28
– – ﹤0.01% 4050
2024
Q4 		$158 Sell
28
-1
-3% -$6 ﹤0.01% 3710
2024
Q3 		$140 Hold
29
– – ﹤0.01% 3728
2024
Q2 		$144 Sell
29
-60
-67% -$377 ﹤0.01% 3548
2024
Q1 		$1.14K Buy
89
+73
+456% +$968 ﹤0.01% 2721
2023
Q4 		$223 Buy
16
+14
+700% +$174 ﹤0.01% 3207
2023
Q3 		$27 Buy
+2
New +$32 ﹤0.01% 2588

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Farther Finance Advisors's VERV Position: Q3 2025 in Review

Farther Finance Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,477 shares — an estimated $27.8K sold.

Farther Finance Advisors first reported a position in VERV in Q3 2023 and held it in 8 quarters. The position peaked at $27.8K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Farther Finance Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 2,477 Verve Therapeutics shares in Q3 2025, an estimated $27.8K.
  • Farther Finance Advisors first reported a position in Verve Therapeutics in Q3 2023 and held it in 8 quarters.
  • Farther Finance Advisors's Verve Therapeutics position peaked at $27.8K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Farther Finance Advisors's 13F filing for Q3 2025, filed 14 Oct 2025.